Company intelligence / Profile preview

Yantai BeBetter Biotech

Guangzhou, Guangdong, Chinabiopharmguy.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Lead program BEBT-908 is a first-in-class PI3K/HDAC dual-target inhibitor, NDA accepted in China for r/r DLBCL. Demonstrated broad-spectrum anti-tumor activity, selected for Chinese national major drug innovation projects, and designated "Breakthrough Therapy"; other drugs in pipeline at Phase 2-3 in hematologic and solid tumors

Therapeutic areas: OncologyGastroenterology
Modalities: Small moleculesiRNAOligonucleotide
Industry: Biotech

Drug pipeline

1 asset

BA2101

Phase 2

Indications: Asthma, COPD, Atopic dermatitis, Chronic rhinosinusitis with nasal polyps, Prurigo nodularis, Chronic spontaneous urticaria

Beyond the preview

Go deeper on Yantai BeBetter Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yantai BeBetter Biotech.

Explore the full profile